Olahype F Tablet contains Fluoxetine 20mg, a selective serotonin reuptake inhibitor (SSRI), and Olanzapine 10mg, an atypical antipsychotic. This combination is primarily used for depression with psychotic features, bipolar depression, and treatment-resistant mood disorders.
The dual-action formulation helps in stabilizing mood, reducing depressive symptoms, controlling hallucinations or delusions, and improving overall psychiatric function. By targeting multiple neurotransmitters, it provides comprehensive management for complex mental health conditions.
Belonging to the CNS and psychiatry segment, Olahype F Tablet is widely prescribed in hospitals, psychiatric clinics, and mental health centers. Its effectiveness in combination therapy ensures high patient adherence and repeat demand.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Olahype F Tablet offers a profitable B2B opportunity, catering to the growing market for advanced psychiatric and CNS therapies across India.